Destiny Pharma to acquire Phase 3 ready C.difficile program and announces fund raising

Destiny  Pharma plc (AIM:DEST) a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections, today announces a fundraise of up to £11.5 million (before expenses) comprising the Placing, Subscription and Open Offer.
The Fundraising will allow Destiny Pharma to acquire the global rights to NTCD-M3, a Phase III ready asset for
prevention of C. difficile infection (CDI) recurrence (the “Acquisition”). Funds will also enable the completion of
Phase III clinical trial preparations, primarily CMC and clinical planning as well as providing additional working

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...